Valneva: to produce Covid vaccine with IDT Biologika
(CercleFinance.com) - On Monday Valneva and IDT Biologika announced their collaboration for the production of VLA2001, Valneva's inactivated COVID-19 vaccine candidate.
The collaboration follows last week's announcement of an agreement between Valneva and the European Commission to supply up to 60 million doses of VLA2001 over two years.
As part of the agreement, IDT Biologika will produce the active ingredient of VLA2001 at its biosafety level 3 facility in Dessau-Roßlau, Germany, in addition to Valneva's production at its site in Livingston, Scotland.
Delivery of the vaccine in Europe is currently scheduled for April 2022, subject to regulatory approval by the European Medicines Agency (EMA), which is expected to begin a phased review of the VLA2001 data soon.
The Valneva share was in pole position in Paris yesterday, closing up almost 10% at 28.5 euros.
Copyright (c) 2021 CercleFinance.com. All rights reserved.